Revolution Medicines (RVMD) Q2 2025 earnings summary

Executive summary

• Advanced multiple clinical-stage RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, with significant progress in pancreatic and NSCLC programs and several Phase 3 trials ongoing or planned for 2025–2026.

• Daraxonrasib and elironrasib received FDA Breakthrough Therapy Designations in key indications, highlighting clinical progress.

• Robust clinical trial enrollment and global expansion, with new registrational trials and pivotal data readouts anticipated in 2025–2026.

• Expanded collaborations with Summit Therapeutics, Iambic, Tango, Aethon, and Break Through Cancer to enhance pipeline and discovery capabilities.

• Secured a $2 billion flexible funding agreement with Royalty Pharma to support global development and commercialization plans.

Financial highlights

• Ended Q2 2025 with $2.1 billion in cash, cash equivalents, and marketable securities, including $250 million from Royalty Pharma.

• Q2 2025 R&D expenses were $224.1 million, up from $134.9 million in Q2 2024, driven by increased clinical and manufacturing activities.

• G&A expenses rose to $40.6 million from $21.7 million year-over-year, reflecting higher headcount and commercial preparation.

• Net loss for Q2 2025 was $247.8 million, compared to $133.2 million in Q2 2024.

• Raised $250 million upfront from a royalty sale agreement and secured a $750 million term loan facility with Royalty Pharma.

Outlook and guidance

• Projected full-year 2025 GAAP net loss between $1.03 billion and $1.09 billion, including $115–$130 million in non-cash stock-based compensation.

• Expect to complete enrollment for the RASolute 302 phase III trial in 2025, with data readout anticipated in 2026.

• Plans to initiate first-line and adjuvant pancreatic cancer registrational trials and a first-line NSCLC trial in 2026.

• Anticipates continued increase in R&D and G&A expenses as clinical programs advance and commercial preparations intensify.

• Expects existing cash and investments to fund operations for at least 12 months from the report date.